Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INCYTE CORPINCY · Entity 3182 | CMO & Head of Late-Stage Dev. | July 16, 2026 | July 20, 2026 |
| Kura Oncology, Inc.KURA · Entity 4871 | Director | June 21, 2022 | June 23, 2022 |
| Repare Therapeutics Inc.RPTX · Entity 68433 | Director | June 17, 2024 | June 20, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INCYTE CORP
Report date July 16, 2026 · Filed July 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,118 |
Reported balance
After 2026-07-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-16 · Sale · Disposed 1,877 · Balance 21,118 |
| Common StockSEC Table I · non-derivative | Direct | 30,916 |
Reported balance
After 2026-07-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-16 · Grant · Acquired 9,798 · Balance 30,916 F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2029-07-16 | Direct | 24,496 |
Reported balance
After 2026-07-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-16 · Grant · Acquired 24,496 · Balance 24,496 F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $116.65 · Expires 2036-07-15 | Direct | 42,298 |
Reported balance
After 2026-07-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-16 · Grant · Acquired 42,298 · Balance 42,298 F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: |
Filing footnotes · ownership attribution and instrument terms
F1: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis.
F2: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested.
F3: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer.
F4: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks:
Kura Oncology, Inc.
Report date June 21, 2022 · Filed June 23, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase common stockSEC Table II · derivative / convertible security · Conversion / exercise price $14.84 · Expires 2032-06-20 | Direct | 23,000 |
Reported balance
After 2022-06-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-06-21 · Grant · Acquired 23,000 · Balance 23,000 F1: This option vests in full on the one year anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests in full on the one year anniversary of the date of grant.
Repare Therapeutics Inc.
Report date June 17, 2024 · Filed June 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.80 · Expires 2034-06-16 | Direct | 54,000 |
Reported balance
After 2024-06-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-17 · Grant · Acquired 54,000 · Balance 54,000 F1: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Theseus Pharmaceuticals, Inc.
Report date February 14, 2024 · Filed February 14, 2024
Section 16 reporting ended · disclosed 2024-02-14. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-02-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-14 · Disposition to issuer · Disposed 3,250 · Balance 0 F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger.
F2: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share.
F3: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 42,298 | $0.00 Strike: $116.65 | $0.00 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · derivative · entry 4 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,298 Underlying: Common Stock · 42,298 shares Expires 2036-07-15 F4 · derivative.exercise_date: The July 16, 2026 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Remarks: Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 24,496 | $0.00 | $0.00 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,496 Underlying: Common Stock · 24,496 shares Expires 2029-07-16 F3 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F3 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2026 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 9,798 | $0.00 | $0.00 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,916 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 16, 2026 grant, this includes an aggregate of 29,338 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance stock units that have not vested. Read SEC document |
| July 16, 2026 Filed Jul 20, 2026 20:10 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 1,877 | $114.73 | $215,348.21 |
DisclosureSEC source: 0001673776-26-000019 · wk-form4_1784578217.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,118 Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:07 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 3,088 | $115.09 | $355,397.92 |
DisclosureSEC source: 0001673776-26-000017 · wk-form4_1784232424.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,995 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 19,540 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 15, 2026 Filed Jul 16, 2026 20:07 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 28,237 | $113.05 | $3,192,192.85 |
DisclosureSEC source: 0001673776-26-000017 · wk-form4_1784232424.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,083 Read SEC document |
| July 14, 2026 Filed Jul 16, 2026 20:07 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 21,830 | $114.88 | $2,507,830.40 |
DisclosureSEC source: 0001673776-26-000017 · wk-form4_1784232424.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,320 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 02, 2026 Filed Jul 7, 2026 20:09 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 2,177 | $116.86 | $254,404.22 |
DisclosureSEC source: 0001673776-26-000015 · wk-form4_1783454944.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,150 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 73,591 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| May 06, 2026 Filed May 20, 2026 20:02 UTC Amendment | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 44,124 | $0.00 | $0.00 |
DisclosureSEC source: 0001673776-26-000013 · wk-form4a_1779307328.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 78,327 F1 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on May 6, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuer's Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three-year performance period ranges from 0% to 150% of the number of performance shares awarded. F2 · shares: This Form 4/A amends the original Form 4, filed on April 17, 2026, to reflect the Compensation Committee's determination on May 6, 2026 relating to the achievement of the performance criteria, which superseded the Compensation Committee's initial determination on April 15, 2026. F3 · balance_after: Including this certification of performance shares, this includes an aggregate of 78,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| April 15, 2026 Filed Apr 17, 2026 20:12 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 39,049 | $0.00 | $0.00 |
DisclosureSEC source: 0001673776-26-000010 · wk-form4_1776456744.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · CMO & Head of Late-Stage Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,252 F1 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 15, 2026. The earned shares will vest on the third anniversary of the July 14, 2023 grant date, subject to the Reporting Person's continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2023 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 73,252 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:06 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 19,932 | $0.00 Strike: $106.21 | $0.00 |
DisclosureSEC source: 0001673776-26-000006 · wk-form4_1769029586.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,932 Underlying: Common Stock · 19,932 shares Expires 2036-01-15 F1 · derivative.exercise_date: Beginning January 16, 2026, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2026 and the remainder vesting monthly over three years. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 21:03 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 15,634 | $101.70 | $1,589,977.80 |
DisclosureSEC source: 0001673776-26-000004 · wk-form4_1767819809.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,203 F1 · balance_after: This includes an aggregate of 34,203 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:05 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 13,292 | $98.77 | $1,312,850.84 |
DisclosureSEC source: 0001673776-26-000002 · wk-form4_1767647119.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,837 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 34,203 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 21:36 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 20,105 | $102.51 | $2,060,963.55 |
DisclosureSEC source: 0001673776-25-000006 · wk-form4_1764797802.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,129 F2 · balance_after: This includes an aggregate of 63,129 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:36 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 17,093 | $102.04 | $1,744,169.72 |
DisclosureSEC source: 0001673776-25-000006 · wk-form4_1764797802.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,234 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 21:36 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 2,559 | $102.96 | $263,474.64 |
DisclosureSEC source: 0001673776-25-000006 · wk-form4_1764797802.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,327 Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,044 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · derivative · entry 7 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,044 shares Expires 2026-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in full on January 7, 2020. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 2,995 | $0.00 Strike: $95.76 | $0.00 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · derivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,995 shares Expires 2026-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Beginning January 7, 2016, options become exercisable in full on January 7, 2020. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 1,194 | $0.00 Strike: $83.83 | $0.00 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · derivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,194 shares Expires 2026-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Beginning July 15, 2016, options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 5,233 | $102.20 | $534,812.60 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,886 F1 · balance_after: This includes an aggregate of 100,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,044 | $95.76 | $99,973.44 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,119 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 2,995 | $95.76 | $286,801.20 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 107,075 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 05, 2025 Filed Nov 7, 2025 21:01 UTC | INCYTE CORP INCY · Entity 3182 | Exercise / conversionCommon Stock | 1,194 | $83.83 | $100,093.02 |
DisclosureSEC source: 0001673776-25-000004 · wk-form4_1762549267.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,080 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2025 Filed Jul 23, 2025 19:56 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 3,706 | $67.94 | $251,785.64 |
DisclosureSEC source: 0000879169-25-000095 · wk-form4_1753300580.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,886 F1 · balance_after: This includes an aggregate of 100,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 27,629 | $0.00 Strike: $68.25 | $0.00 |
DisclosureSEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · derivative · entry 6 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,629 Underlying: Common Stock · 27,629 shares Expires 2035-07-14 F5 · derivative.exercise_date: The July 15, 2025 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantPerformance Shares · Derivative | 30,692 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · derivative · entry 5 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,692 Underlying: Common Stock · 30,692 shares Expires 2028-07-15 F4 · derivative.exercise_price: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. F4 · derivative.exercise_date: Each performance share represents the right to receive up to 200% of one share of common stock. Such shares may be earned based upon the issuer's relative total shareholder return ("TSR") over a three-year performance period beginning on January 1, 2025 as compared to the TSR of companies in a fixed peer group, as set forth in the Performance Share Award Agreement. The earned shares will vest on the third anniversary of the grant date subject to the Reporting Person's continued service with the issuer. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 12,277 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · nonDerivative · entry 4 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 106,592 F2 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years. The RSUs may be settled only for shares of common stock on a one-for-one basis. F3 · balance_after: Including the July 15, 2025 grant, this includes an aggregate of 100,327 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 15, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,596 | $68.25 | $108,927.00 |
DisclosureSEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · nonDerivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 94,315 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,555 | $69.98 | $108,818.90 |
DisclosureSEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,911 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. Read SEC document |
| July 14, 2025 Filed Jul 16, 2025 20:05 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 14,952 | $68.47 | $1,023,763.44 |
DisclosureSEC source: 0000879169-25-000085 · wk-form4_1752696308.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,466 Read SEC document |
| July 02, 2025 Filed Jul 7, 2025 20:48 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 12,714 | $68.17 | $866,713.38 |
DisclosureSEC source: 0000879169-25-000076 · wk-form4_1751921297.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,418 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 94,907 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:50 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 20,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-016576 · wk-form4_1743713415.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,132 F2 · shares: Represents the shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on the third anniversary of the July 2, 2022 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, specified development, revenue and market-based (relative total shareholder returns compared to the Nasdaq Biotechnology Index) performance goals determined by the Issuers Compensation Committee in January 2022 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F3 · balance_after: This includes an aggregate of 122,573 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| April 01, 2025 Filed Apr 3, 2025 20:50 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 37,198 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-016576 · wk-form4_1743713415.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,165 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on April 1, 2025. The earned shares will vest on November 30, 2025, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, achievement of specified Opzelura performance goals. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. Read SEC document |
| January 21, 2025 Filed Jan 22, 2025 21:05 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 12,352 | $72.69 | $897,866.88 |
DisclosureSEC source: 0000879169-25-000032 · wk-form4_1737579939.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 66,967 F1 · balance_after: This includes an aggregate of 64,408 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| January 17, 2025 Filed Jan 22, 2025 21:05 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 28,202 | $0.00 Strike: $71.93 | $0.00 |
DisclosureSEC source: 0000879169-25-000032 · wk-form4_1737579939.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,202 Underlying: Common Stock · 28,202 shares Expires 2035-01-16 F2 · derivative.exercise_date: Beginning January 17, 2025, options become exercisable in 37 installments, with the first 25% vesting on July 15, 2025 and the remainder vesting monthly over three years. Read SEC document |
| January 15, 2025 Filed Jan 17, 2025 20:31 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 10,692 | $72.46 | $774,742.32 |
DisclosureSEC source: 0000879169-25-000016 · wk-form4_1737145906.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,319 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 64,408 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| August 12, 2024 Filed Aug 14, 2024 19:37 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 11,608 | $60.63 | $703,793.04 |
DisclosureSEC source: 0000879169-24-000151 · wk-form4_1723664231.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,011 F1 · balance_after: This includes an aggregate of 87,452 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 31,088 | $0.00 Strike: $64.25 | $0.00 |
DisclosureSEC source: 0000879169-24-000139 · wk-form4_1721233859.xml · derivative · entry 3 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,088 Underlying: Common Stock · 31,088 shares Expires 2034-07-14 F4 · derivative.exercise_date: The July 15, 2024 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:31 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 1,555 | $64.25 | $99,908.75 |
DisclosureSEC source: 0000879169-24-000139 · wk-form4_1721233859.xml · nonDerivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,619 F2 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F3 · balance_after: Including the July 15, 2024 grant, this includes an aggregate of 87,452 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 15, 2024 Filed Jul 17, 2024 16:31 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 13,895 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000139 · wk-form4_1721233859.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,174 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to the employee's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 16:17 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 8,316 | $59.02 | $490,810.32 |
DisclosureSEC source: 0000879169-24-000112 · wk-form4_1720023464.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,279 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 76,940 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| June 17, 2024 Filed Jun 20, 2024 20:35 UTC | Repare Therapeutics Inc. RPTX · Entity 68433 | GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $3.80 | $0.00 |
DisclosureSEC source: 0001415889-24-017653 · form4-06202024_040601.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Shares · 54,000 shares Expires 2034-06-16 F1 · derivative.exercise_date: One-third (1/3rd) of the shares subject to the option shall vest on June 17, 2025, and one twenty-fourth (1/24th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to provide service through each such date. Read SEC document |
| February 14, 2024 Filed Feb 14, 2024 16:03 UTC | Theseus Pharmaceuticals, Inc. THRX · Entity 94301 | Disposition to issuerRestricted Stock Units · Derivative | 3,250 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-023576 · tm246087-6_4seq1.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,250 shares Expires not disclosed F1 · derivative.exercise_price: Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of December 22, 2023, by and among the Issuer, Concentra Biosciences, LLC, a Delaware limited liability company ("Parent") and Concentra Merger Sub II, Inc., a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of February 14, 2024 (the "Effective Time") with the Issuer surviving the merger. F2 · derivative.exercise_price: Each Issuer restricted stock unit ("Issuer RSU") represents a contingent right to receive one Share. F3 · price: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, each outstanding Issuer RSU that was outstanding and unvested immediately prior to the Effective Time vested in full. At the Effective Time, each Issuer RSU then outstanding was cancelled and converted into (i) a cash payment equal to the product of (A) the total number of Shares then underlying such Issuer RSU multiplied by (B) $4.05 per Share in cash, without interest and subject to any withholding of taxes; and (ii) one non-transferable contractual contingent value right per Share subject to such Issuer RSU, which represents the right to receive potential payments, in cash, subject to any applicable tax withholding and without interest, all upon the terms and subject to the conditions as set forth in the Offer to Purchase, as amended, and in the related Letter of Transmittal. Read SEC document |
| February 14, 2024 Filed Feb 16, 2024 17:49 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 7,377 | $0.00 | $0.00 |
DisclosureSEC source: 0000879169-24-000058 · wk-form4_1708105761.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,595 F1 · shares: Represents shares of common stock underlying performance shares earned upon the achievement of performance criteria determined to be satisfied on February 14, 2024. The earned shares will vest on the third anniversary of the July 2, 2021 grant date, subject to the Reporting Persons continued service with the Issuer. Each performance share represents the right to receive one or more shares of common stock based on, and subject to, the achievement of specified financial and development performance criteria determined by the Issuers Compensation Committee in January 2021 as set forth in the Performance Share Award Agreement. The number of shares of common stock that the Reporting Person is entitled to receive over the three year performance period ranges from 0% to 150% of the number of performance shares awarded. F2 · balance_after: This includes an aggregate of 95,036 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| January 18, 2024 Filed Jan 22, 2024 18:02 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 30,580 | $0.00 Strike: $61.18 | $0.00 |
DisclosureSEC source: 0000879169-24-000030 · wk-form4_1705946556.xml · derivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,580 Underlying: Common Stock · 30,580 shares Expires 2034-01-17 F1 · derivative.exercise_date: Beginning January 18, 2024, options become exercisable in 37 installments, with the first 25% vesting on July 14, 2024 and the remainder vesting monthly over three years. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 17:27 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 7,365 | $65.51 | $482,481.15 |
DisclosureSEC source: 0000879169-24-000008 · wk-form4_1704475619.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,218 F1 · balance_after: This includes an aggregate of 87,659 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | SaleCommon Stock | 21,511 | $63.28 | $1,361,216.08 |
DisclosureSEC source: 0001209191-23-044393 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,583 F1 · balance_after: This includes an aggregate of 87,659 shares of common stock issuable pursuant to previously reported restricted stock units and earned performance shares that have not vested. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantEmployee Stock Option (right to buy) · Derivative | 28,385 | $0.00 Strike: $61.76 | $0.00 |
DisclosureSEC source: 0001209191-23-042550 · doc4.xml · derivative · entry 2 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,385 Underlying: Common Stock · 28,385 shares Expires 2033-07-13 F3 · derivative.exercise_date: The July 14, 2023 options become exercisable in 37 installments, with the first 25% vesting after one year and the remainder vesting monthly over three years. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | GrantCommon Stock | 13,535 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-042550 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 119,094 F1 · shares: Represents award of restricted stock units ("RSUs") that will vest 25% annually over four years, subject to Steven Stein's continued service with the issuer through the applicable vesting dates. The RSUs may be settled only for shares of common stock on a one-for-one basis. F2 · balance_after: Including the July 14, 2023 RSU Grant, this includes an aggregate of 87,659 shares of common stock issuable pursuant to previously RSUs and earned performance shares that have not vested. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:00 UTC | INCYTE CORP INCY · Entity 3182 | Tax withholdingCommon Stock | 8,442 | $62.08 | $524,079.36 |
DisclosureSEC source: 0001209191-23-041511 · doc4.xml · nonDerivative · entry 1 Stein Steven H · CIK 0001673776 · EVP & Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,559 F1 · shares: Represents shares withheld automatically by the Issuer to satisfy tax withholding obligations due at settlement of RSUs or earned performance shares previously reported in Table I as common stock. F2 · balance_after: This includes an aggregate of 74,124 shares of common stock issuable pursuant to previously RSUs and earned performance shares that have not vested. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.